Selames 60 mg spot-on solution for dogs 5.1–10.0 kg

Authorised

- Selamectin

Product identification

Medicine name:
Selames 60 mg spot-on solution for dogs 5.1–10.0 kg
Selames 60 mg spot-on oplossing voor honden 5,1 – 10,0 kg

Active substance:
Selamectin

Target species:
Dog

Route of administration:
Spot-on use

Product details

Active substance and strength:
Selamectin
60.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:
Spot-on solution

Withdrawal period by route of administration:

Spot-on use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP54AA05

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Netherlands

Package description:
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spike packaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. Cardboard box containing 1 pipette.
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spike packaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. Cardboard box containing 3 pipettes.
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spike packaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. Cardboard box containing 6 pipettes.
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spike packaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. Cardboard box containing 15 pipettes.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:
20/11/2018

Manufacturing sites for batch release:
Tad Pharma GmbH
Krka d.d. Novo Mesto

Responsible authority:
Medicines Evaluation Board

Authorisation number:
REG NL 122210

Date of authorisation status change:
26/01/2022

Reference member state:
Ireland

Procedure number:
IE/V/0407/002

Concerned member states:
Belgium France Germany Italy Netherlands Portugal Spain
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics
